Tyrosine phosphorylation is a common means of regulating protein functions and signal transduction in multiple cells. Protein tyrosine phosphatases (PTPs) are a large family of signaling enzymes that remove phosphate groups from tyrosine residues of target proteins and change their functions.
A C C E P T E D M A N U S C R I P T 4 et al., Uetani et al., 2000; Yeo et al., 1997) . Among these three RPTPs, LAR and PTPσ have been shown to be important functional receptors that bind chondroitin sulfate proteoglycans (CSPGs) with high affinity and mediate their inhibitory effects through the convergent and divergent signaling pathway (Fisher et al., 2011; Ohtake and Li, 2015; Ohtake et al., 2016; Shen et al., 2009) . Following CNS injury, severed axons fail to regenerate in adult mammalians partly due to upregulation of various inhibitory ECM molecules around the lesion, especially the potent axon growth inhibitors of CSPGs. Whether PTPδ functions as a receptor of CSPGs remains to be determined.
Multiple PTPs are expressed preferentially in the haematopoietic system and some of them have been implicated in regulating development and functions in the immune system (Pike and Tremblay, 2013) . Altered PTP activities may induce inappropriate proliferation, survival and activation of immune cells, and contribute to pathophysiology of inflammation and autoimmunity diseases. Thus, PTPs have the complex and diverse functions in the immune system and may become molecular targets for treating immune related disorders. Out of the three type-IIa RPTPs, LAR is expressed on immature thymocytes although its phosphatase activity appears unnecessary for T cell development and function (Kondo et al., 2010; Terszowski et al., 2001) . LAR and PTPσ are specifically coexpressed in murine plasmacytoid dendritic cells (pDCs) and deletion of both simultaneously increases interferon production by pDCs (Bunin et al., 2015) . Recently, we demonstrate that PTPσ is expressed in multiple immune cells, including DCs, and is critical for regulating their activation, cytokine production and immune-mediated inflammation (Ohtake et al., 2017) . Because PTPσ is highly expressed in both nervous and immune systems and has crucial functions in both systems, this review will focus on the diverse functions of PTPσ and its related genes, and their significance in mediating neurological and autoimmune disorders.
RPTPs regulates neuronal growth and synapse formation during development
Three type-IIa RPTPs show divergent distribution patterns in the developmental nervous system.
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A C C E P T E D M A N U S C R I P T 5 PTPσ is widely expressed throughout the central and peripheral nervous system during embryonic development. The high levels of its mRNA are especially detected in several structures, including ventricular and subventricular zones, cortex, dorsal root ganglia (DRG), cranial nerve ganglia, olfactory epithelium, and retina (Wang et al., 1995) . During postnatal development, its expression levels decrease in most brain regions, although certain areas still exhibit high levels, such as hippocampus. In contrast, LAR mRNA is expressed in neural and non-neural tissues with different patterns from PTPσ. High levels of LAR mRNA are detected in epithelial layer of various embryonic tissues and in neuroepithelium and DRGs during embryogenesis. LAR expression shows developmental regulation during neural cell growth and differentiation (Longo et al., 1993) . During embryonic development, PTPδ expression is relatively low and limited to differentiated cells of several structures, including olfactory bulb, cortical plate, thalamic nuclei, and olivary nucleus (Schaapveld et al., 1998; Sommer et al., 1997) .
RPTPs are localized to the growth cone at axonal tip of immature neurons, while they are largely localized to the dendritic spines and excitatory synapse of mature neurons (Wyszynski et al., 2002) .
RPTPs are localized to distinct types of synapses. In culture hippocampal neurons, PTPσimmunostained puncta overlapped with the axonal vesicular glutamate transport protein 1, indicating its localization to CNS axons (Takahashi et al., 2011) . LAR is concentrated in mature synapses in hippocampal neuronal cultures, and is vital for development and maintenance of excitatory synapses.
LAR knockdown causes loss of excitatory synapses and dendritic spines, decrease of surface AMPA receptors, impaired dendritic targeting of cadherin-beta-catenin complex and dysfunction in excitatory synapses (Dunah et al., 2005; Woo et al., 2009) . In contrast, in addition to expression in excitatory synapses, PTPδ accumulates in inhibitory presynapses and regulates their genesis by interacting with postsynaptic adhesion molecule Slit and Trk-like family proteins 3 (Slitrk3) (Takahashi et al., 2012) . Thus, individual RPTPs appear to target different synapse types probably by binding to diverse ligands in distinct types of synapses.

A C C E P T E D M A N U S C R I P T
6 RPTPs, including PTPσ and LAR, mediate various cell-ECM adhesions by binding some extracellular ligands, such as heparan sulfate proteoglycans (HSPGs) and CSPGs (Aricescu et al., 2002; Coles et al., 2011; Johnson et al., 2006) (Dickendesher et al., 2012; Fisher et al., 2011; Shen et al., 2009) . PTPσ binds to CS-D, CS-E, and DS, but not to CS-A or CS-C (Dickendesher et al., 2012) . Recently, Geller's group demonstrated that the main binding sites for
PTPσ are located to neurons in adult mouse brain, but are not to GAG chains of proteoglycans (Yi et al., 2014) . Further studies are required to clarify these discrepancies.
The highly-controlled sulfation patterns on CS chains are important for mediating CSPG functions (Miller and Hsieh-Wilson, 2015; Yu et al., 2017) although various studies revealed inconsistent results on the roles of different CS chains. CS-E, not CS-A, could suppress outgrowth of both cerebral cortical and DRG neurons (Brown et al., 2012; Butterfield et al., 2010; Karumbaiah et al., 2011; Verna et al., 1989) , but CS-E was also reported to promote neurite growth of hippocampal and cortical neurons (Pulsipher et al., 2014; Tully et al., 2004) . CS-C was either inhibitory or noninhibitory to neurite growth reported by different groups (Brown et al., 2012; Butterfield et al., 2010) . In contrast, CS-A, not CS-C, was found inhibitory to neurite growth of cerebellar granule
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A C C E P T E D M A N U S C R I P T 7 cells . Therefore, it will be important to further elucidate the spatiotemporal regulation and precise functions of various CS chains, their specific molecular interactions and downstream signaling pathways.
CS and HS chains share common uronic sugar residues (glucuronic acid and iduronic acid) and a linkage region of xylose-galactose, but they consist of different amino sugar disaccharides, the Nacetylgalactosamine for CS and the N-acetylglucosamine for HS added by distinct enzymes (Lindahl et al., 2015; Yu et al., 2017) . CSPGs and HSPGs regulate growth, guidance, and connections of CNS neurons, but these two subclasses of sulfated proteoglycans have distinct functions on neuronal growth, typically with suppression by the former and promotion by the latter on axonal elongation (Bandtlow and Zimmermann, 2000; Coles et al., 2011; Silver and Miller, 2004) . Presence of CSPGs remarkably attenuated neurite outgrowth of cultured DRG neurons (Dill et al., 2008; Snow et al., 1990; Snow and Letourneau, 1992) . In contrast, treatment with HSPGs, including glypican-2, strongly promoted elongation of cultured neurons in vitro (Coles et al., 2011; Hantaz-Ambroise et al., 1987; Lander et al., 1982) .
HSPGs and CSPGs regulate axon growth during development through their HS or CS chains. HS treatment induced axon defasciculation and growth in incorrect directions in cultured cockroach embryos, while CS treatment had no effect. Enzymatic degradation of HS by heparitinase resulted in axon perturbation, whereas degradation of CS had no effect (Wang and Denburg, 1992) . Similarly, heparin, a glycosaminoglycan containing heparan sulfate, resulted in abnormal axon behavior in retinal ganglion cells from Xenopus laevis embryos (Walz et al., 1997) . CSPGs also play a remarkable role in guiding axons by forming inhibitory areas during development. CSPG expression shows precise spatial and temporal pattern in developing retina. CSPG was detected during retinal development of rat at embryonic day 12.5 (E12.5), gradually decreased from the central area to the periphery, and no longer detectable at E17 (Abbott et al., 2007) . Treatment of cultured embryonic retina with chondroitinase ABC (ChABC) to remove CS GAG chains induced abnormal retinal axon projections into the region where normal axons could not enter (Snow et al., 1991) . Therefore, proteoglycans regulate axon guidance and extension during development probably by interacting with RPTPs, including PTPσ. protein-like 1 (IL1RAPL1) (Valnegri et al., 2011; Yoshida et al., 2011) , its paralog IL1RAPL2 (Pavlowsky et al., 2010; Valnegri et al., 2011; Yoshida et al., 2011) , IL-1 receptor accessory protein (IL-1RAcP) (Yoshida et al., 2012) , and Slitrks (Takahashi et al., 2012; Yim et al., 2013) . Though all three type-IIa RPTPs can bind to NGL-3 through their first two FNIII domains and also to IL-1RAcP, Slitrks bind to PTPσ and PTPδ selectively through the Ig domains. In contrast, TrkC binds to PTPσ and IL1RAPL1 binds to PTPδ only.
A C C E P T E D
Axonal RPTPs accumulate NGL-3 on dendrites and appear to promote excitatory postsynaptic development by interactions with NGL-3 and postsynaptic density protein (PSD-95). NGL-3 mainly induced excitatory presynaptic differentiation of contacting axons in co-cultured system and this effect is suppressed by treatment with soluble LAR ectodomain (Woo et al., 2009) . Induced aggregation of NGL-3 on dendrites resulted in dendritic clustering of excitatory, but not inhibitory, postsynaptic proteins, including the scaffold protein PSD-95. Accordingly, the C-terminus of NGL-3 has been shown to bind the PDZ domains of PSD-95 (Kim et al., 2006) . Although all three type IIa RPTPs can bind and interact with NGL-3, PTPσ appears to be the main presynaptic component based on their exclusive excitatory synaptic localization, affinity for NGL-3 and expression pattern in the brain.
Presynaptic PTPσ interacts with postsynaptic TrkC and seems to regulate development of excitatory
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A C C E P T E D M A N U S C R I P T 9 synapses transduced by the intracellular domain of PTPσ. Trks, a family of tyrosine kinases, are well characterized as the receptors of neurotrophic factors that control neural survival, differentiation, proliferation, the fate of neural precursors, axon and dendrite growth and patterning. With unbiased expression screen in co-culture system, PTPσ, but not PTPδ and LAR, was identified as a TrkC binding partner (Takahashi et al., 2011) . Moreover, TrkC induced excitatory, but not inhibitory, presynaptic differentiation and this effect is abolished by axonal expression of mutated PTPσ lacking the intracellular region.
RPTPs promote excitatory synapse development also by interacting with members in the IL-1/Toll receptor family (IL1RAPL1, IL1RAPL2 and IL1RAcP) and activating PSD-95 and Jun-N-terminal kinase (JNK) signaling pathways. IL1-RAcP interacts with all three type IIa RPTPs, although IL1RAPL1 binds PTPδ, but not PTPσ and LAR. IL1RAPL1-PTPδ interactions recruited GTPaseactivating protein to regulate excitatory synapse formation, as well as dendritic synapse number and morphogenesis (Valnegri et al., 2011; Yoshida et al., 2011) . IL-1RAcP includes two isoforms, the ubiquitously-expressed IL-1RAcP and the CNS-specific IL-1RAcPb (Smith et al., 2009 ). Both isoforms regulate differentiation of excitatory presynapses, while IL-1RAcPb also contributes to formation of dendritic spines. Because IL-1RAcP interacted with PTPδ through the extracellular domain and the IL-1RAcP-mediated formation of presynapses is partly abolished in cortical neurons derived from PTPδ-deficient mice (Yoshida et al., 2012) , the interactions of IL-1RAcP with other RPTPs, such as PTPσ and/or LAR, may also play a significant role in this action. Given that IL1RAPL1-dificient neurons have reduced levels of phosphorylated PSD-95 and JNK proteins, these signaling pathways appear to mediate the RPTP-IL1RPL1 interactions (Pavlowsky et al., 2010) .
Slitrks play important roles in regulating synapse development by forming protein complex with
RPTPs (Yim et al., 2013) . Slitrks are a family of transmembrane receptors that contain six leucinerich repeat domains. All six members (Slitrk1-6) are able to induce presynaptic differentiation in
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10 neuronal co-cultures. Five Slitrks, except for Slitrk3, could interact with PTPσ and contribute to excitatory synaptogenic activities. Only Slitrk3 can induce inhibitory, but not excitatory, presynaptic differentiation in vitro and in vivo by interact with presynaptic PTPδ (Takahashi et al., 2012) . Of note, because CSPG plays an important role in restricting neuronal plasticity following injury, interactions of RPTPs with postsynaptic adhesion molecules during development may also be regulated by competing with CSPGs in a spatiotemporal manner.
PTPσ mediates neuroplasticity in mature neurons
Although a number of brain regions show obvious mRNA distribution of PTPσ, LAR and PTPδ in the adult mice, their expression patterns are very diverse (Schaapveld et al., 1998; Shishikura et al., 2016; Wang et al., 1995) . During postnatal development, the expression level of PTPσ decrease dramatically in most brain regions, but high levels continue to be detected in hippocampus, especially the pyramidal cell layer (Kwon et al., 2010) . Strong signals for PTPσ are also detected in several other areas of adult mammals, including the internal granule layer of olfactory bulb, piriform cortex, tenia tecta, septal area and cerebellum. Strong LAR signals are found in the internal granule layer of olfactory bulb, subventricular zone of caudate putamen and cerebellum, but are less abundantly in layer IV of cortex and septal area. In contrast, PTPδ protein or mRNA is expressed in the hippocampus (particularly the CA2 and CA3 regions), layer IV of cortex, granule cell layer of cerebellum, thalamic nuclei, and mitral and granular cell layers of the olfactory bulb, but it is undetectable in septal area. Therefore, three type IIa RPTPs exhibit overlapping, but differential distribution patterns in the developed brain.
PTPσ modulates the neuronal plasticity in mature neurons. PTPσ-deficient mice exhibit severe growth retardation, high neonatal mortality and neurological deficiencies, including thinning of the corpus callosum and cerebral cortex, hippocampal dysgenesis, abnormal pituitary development, motor dysfunction and defective proprioception (Meathrel et al., 2002; Uetani et al., 2006) . PTPσ
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A C C E P T E D M A N U S C R I P T 11 null mice also have increased hippocampal mossy fibers and axon sprouting during aging, consistent with PTPσ limiting synapse formation. PTPσ deficiency increases the frequency of miniature postsynaptic currents mediated by α-amino-3-hydroxy5-methyl-4-isoxazolepropionic acid (AMPA) receptor, accompanied by an increase in synapse density, but decreases synaptic efficiency.
Moreover, the role of PTPσ in CNS plasticity has been demonstrated in learning and memory. PTPσ null mice show reduced long-term potentiation (LTP, an activity-dependent synaptic plasticity) in hippocampal Schaffer collateral-CA1 synapses and enhanced performance in a novel object recognition memory test (Horn et al., 2012) .
LAR deficient mice have smaller basal forebrain cholinergic neurons and reduced cholinergic innervation of their target neurons in the dentate gyrus (Yeo et al., 1997) . Mice lacking the phosphatase domains of LAR have spatial learning deficiency and hyperactivity (Kolkman et al., 2004) . PTPδ knockout mice also exhibit marked motor dysfunction, impaired visuospatial processing with low survival rates (Uetani et al., 2006; Uetani et al., 2000) , and impaired learning and memory tasks and enhanced LTP (Uetani et al., 2000) . The phenotype differences in deficiency of three RPTPs may result from diverse ligands, subcellular distribution or downstream signaling pathways.
PTPσ regulates synaptic plasticity, learning and memory in adult CNS, but it is unclear whether its function is associated with the interactions with perineuronal nets (PNN) molecules, especially
CSPGs. PNNs are composed of ECM macromolecules (including hyaluronan, CSPGs, tenascin-R, link proteins and other components) and organize these molecules into specific structures (Busch and Silver, 2007; Hagihara et al., 1999; Kwok et al., 2011; Massey et al., 2006) . In extracellular space, , 2011) . PTPσ is one of the two identified RPTP receptors for CSPGs, the major components of PNN (Shen et al., 2009 ), but Geller's group did not detect PTPσ binding to PNN in the mouse brain (Yi et al., 2014) .
Further studies are required to illustrate the molecular mechanisms for PTPσ-mediated neuronal plasticity.
PNNs may play critical roles in the mature CNS, including synapse stabilization, neuroprotection, ionic buffering and neuronal plasticity. PNNs have been implicated to maintain and modify cognition, learning and memory functions. PNN formation in amygdala of mice affects developmental shift in the ability to erase fear memories by extinction (Gogolla et al., 2009 ). ChABC induces similar reduction of LTP in vitro (Bukalo et al., 2001) . Deletion of brevican, one of brain-specific CSPGs, in mutant mice, or treatment of wild-type mice with anti-brevican antibody resulted in impaired LTP, although they exhibited normal behavior and spatial memory (Brakebusch et al., 2002) .
Organization of CSPGs in
PTPσ functions as a CSPG receptor to mediate axon regeneration in the CNS
After CNS injuries, reactive astrocytes generate extremely high levels of CSPGs, which potently suppress axon growth into and beyond the lesion area (Bradbury et al., 2002; Busch and Silver, 2007; Jones et al., 2003) . The major CSPGs expressed in the CNS include lecticans (neurocan, versican, aggrecan, and brevican), phosphacan and NG2. Lecticans share many similar domains at both N-and C-termini of the core proteins and their core proteins are linked by a central CS-GAG anchoring
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A C C E P T E D M A N U S C R I P T 13 backbone bound one or numerous long chain CS-GAG polysaccharide (Yamaguchi, 2000) . Lecticans function as linkers of the ECM molecules. Phosphacan is the extracellular domain of transmembrane RPTPβ. NG2 is a transmembrane CSPG and has no significant homologies to other CSPGs. Because removing GAGs or preventing their sulfation neutralizes most suppression of axon growth by CSPGs in vitro (Gilbert et al., 2005; Sherman and Back, 2008; Wang et al., 2008) , the sulfated GAG chains play crucial roles for CSPG function. CSPGs has been known to impede axon elongation for almost three decades, but the detailed mechanisms are not well known. The general mechanisms identified include binding functional CSPG receptors on neuronal membrane, formation of non-permissive PNNs that causes steric hindrance of growth-promoting adhesion molecules such as laminin and integrins, and facilitating functions of chemo-repulsive molecules, such as Sema 3A and 5A (Condic et al., 1999; Kantor et al., 2004; Tan et al., 2011) . Transmembrane receptors appear important in conveying CSPG inhibition, including PTPσ, LAR, and Nogo receptors 1 and 3 (Dickendesher et al., 2012; Fisher et al., 2011; Lang et al., 2015; Shen et al., 2009; Xu et al., 2015) . Especially, PTPσ and LAR bind CSPGs with high affinity and convey their inhibitions of axon extension after CNS injury.
CSPG neurocan can bind and interact with PTPσ through the CSPG GAG chains and a few positively-charged residues in the first Ig-like domain of PTPσ (Shen et al., 2009 ). DRGs derived from PTPσ deficient mice increased neurite growth on CSPG and this effect was specific to CSPG because PTPσ deletion does not overcome suppression of myelin-associated glycoprotein. PTPσ knockout mice showed regeneration of lesioned ascending sensory neurons into the CSPG-rich lesion area although regenerating axons failed to pass injured area (Shen et al., 2009) Similarly, CSPGs bind LAR dose-dependently also through CSPG GAG chains and the first Ig-like domain of LAR. LAR inhibition by transgenic deletion or pharmacological blockade with sequencetargeting blocking small peptides stimulated regrowth of serotonergic and CST axons, and functional recovery after transection SCI (Fisher et al., 2011; Xu et al., 2015) . As another member of type IIa
RPTPs, whether PTPδ also mediates CSPG suppression as a transmembrane receptor is unknown.
However, PTPδ has recently been reported to contribute to Semaphorin-3A mediated growth cone collapse response in neuronal cultures probably by dephosphorylating tyrosine residues at the Cterminus of Fyn and activing this kinase (Nakamura et al., 2017) . Notably, Semaphorin-3A is a component of PNN together with CSPGs and is able to bind the sugar chains of CSPGs with high affinity (Carulli et al., 2013) .
Both CSPGs and HSPGs are the ligands of PTPσ in nervous system with a similar binding affinity.
Crystallographic analysis suggests that CSPGs can prevent PTPσ dimerization (Fig. 1B) , while HSPGs induce PTPσ clustering (Coles et al., 2014; Coles et al., 2011) . CSPGs and HSPGs share the same binding site of PTPσ in the first Ig-like domain and they compete for PTPσ binding, resulting in opposite effects on axon elongation. CSPGs inhibit axon outgrowth in neurons derived from wildtype mice, but this effect is diminished in PTPσ-deficient neurons (Fry et al., 2010; Sapieha et al., 2005; Shen et al., 2009; Thompson et al., 2003) . In contrast, HSPGs dramatically promote axon outgrowth in wild-type, but not PTPσ-deficient neurons. Therefore, the CSPGs/HSPGs ratio is critical for determining PTPσ dimerization status in regulating axon growth. However, some issues remain regarding the interactions between proteoglycans and RPTPs. The CS-C GAG chain used in
A C C E P T E D M A N U S C R I P T
15 previous study (Coles et al., 2011) did not bind to PTPσ (Dickendesher et al., 2012 (Fisher et al., 2011; Ohtake et al., 2016) . PTPσ and LAR employ a few signaling pathways commonly, including RhoA, Akt, extracellular signal-regulated kinase (Erk) and microtubule-associated protein 1B (MAP1B).
Their actions in transmitting CSPG effects to inhibit axon growth also involve distinct signal molecules, including the use by PTPσ of collapsing response mediator protein 2 (CRMP2, Fig. 1B) , adenomatous polyposis coli (APC), S6 ribosomal protein (S6) and cAMP response element-binding protein (CREB), whereas the use by LAR of cofilin, protein kinase Cζ (PKCζ) and liver kinase B1
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16 (LKB1). Consistent with these results, deletion of both PTPσ and LAR showed additive effects in enhancement of axon growth in adult neurons in vitro. Thus, several intracellular signaling pathways are known to mediate CSPG actions through the RPTP receptors.
Previous reports also suggest that CSPGs use diverse pathways to suppress neuronal growth, including glycogen synthase kinase 3β (GSK3β) and PKC (Dill et al., 2008; Powell et al., 2001) .
Cultured axons contain transcripts encoding RhoA and applying CSPGs to axon compartment enhanced axonal RhoA synthesis (Walker et al., 2012) . Inhibition of RhoA transcripts in axons increased their growth in the presence of CSPGs. Treatment of neurons with LAR inhibitory peptides or deletion of PTPσ elevated both Erk and Akt activities (Sapieha et al., 2005; Xie et al., 2001) . In spite of recent progress in understanding intracellular signals of CSPGs, further studies are required to clarify some issues remained. For examples, Rho/Rock pathways inhibit both cofilin and CRMP2, but only PTPσ inhibits CRMP2 whereas only LAR inhibits cofilin (Ohtake et al., 2016) . Likewise, mTOR/S6 and CREB are activated by Akt and Erk, but only PTPσ inhibits S6 and CREB signaling pathways.
PTPσ regulates functions of immune cells and development of autoimmune diseases
PTPσ is expressed by immune cells and has important functions in the immune system (Fig. 2) .
PTPσ, but not LAR and PTPδ, is expressed in human pDCs controlled by transcription factor E2-2 (Bunin et al., 2015) . PTPσ is rapidly downregulated by pDC activation and its deficiency induces production of interferon α (IFNα) in pDCs. Antibody-mediated forced PTPσ activation inhibited Toll-like receptor 9-mediated pDC activation. pDCs can secrete type I IFN (IFNα or β) rapidly and abundantly in response to various stimuli and regulate viral infections through virus-specific T-cell responses. Accordingly, hyperactivation of pDCs is implicated in several autoimmune diseases, including inflammatory bowel disease (Cervantes-Barragan et al., 2012; Ganguly et al., 2013; Swiecki et al., 2010) . DC-specific deletion of PTPσ in mice with a LAR null background leads to
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17 IFN production by pDCs, leukocyte infiltration and mild spontaneous colitis (Bunin et al., 2015) .
Consistently, three single nucleotide polymorphisms (SNPs) in human PTPRS (PTPσ) gene have been linked to ulcerative colitis, an inflammatory bowel disease characterized by dysregulation of autoimmune responses (Muise et al., 2007) . PTPσ normally functions as a positive regulator of intestinal epithelial barrier by orchestrating epithelial cell adhesion through targeting of adherens junction proteins, including E-cadherin, β-catenin and ezrin (Murchie et al., 2014) . Together, PTPσ is essential to balance DC tyrosine phosphorylation mediated by various kinases (Fujita et al., 2013) and to inhibit tyrosine phosphorylation-dependent pDC activation, spontaneous IFN production and immune-mediated intestinal inflammation.
We recently identified critical role of PTPσ in regulating autoimmune disorders in the nervous system and extended the function of PTPσ in immune system (Ohtake et al., 2017) . We demonstrate that transgenic deletion or pharmacological inhibition of PTPσ significantly exacerbates clinical symptoms and axon/myelin damages in the spinal cord of mice with experimental autoimmune encephalomyelitis (EAE), a widely-used model for multiple sclerosis (MS). Following immunization with myelin oligodendrocyte glycoprotein (MOG) peptide, PTPσ knockout mice showed proinflammatory responses in the spinal cord and lymphoid organs by changing expression levels of various inflammatory-related genes, including specific cytokines (Ifng and Il17a) and chemokines (Ccl2, Ccl5 and Cxcl10) (Ohtake et al., 2017) . Interestingly, PTPσ deficiency stimulated activation of conventional DCs (cDCs), affected differentiation of CD4+ T lymphocytes directly, reduced number of regulatory T (Treg) cells, and facilitated infiltration of T cells and activation of macrophages and microglia in the CNS (Fig. 2) . Moreover, adoptive transfer of PTPσ-deficient cDCs stimulated with lipopolysaccharide to wild-type mice augmented EAE clinical symptoms following pulsed MOG35-55 peptide immunization. PTPσ deletion also enhanced expression of genes mediating immune responses, including Tbx21 in Th1 and Rorc in Th17 cells (Ohtake et al., 2017) . Consistently, PTPσ deficiency has been reported to reduce expression level of Foxp3, a lineage-specific marker for Treg
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18 (Fontenot et al., 2005; Ziegler, 2006) , which delay the onset of spontaneous EAE (Lowther et al., 2013) . Therefore, PTPσ is an important negative regulator for activation of pro-inflammatory responses of cDCs, differentiation of CD4+ T cells into Th1 and Th17 cells, and development of a CNS autoimmune disease. Notable, it is interesting to determine whether PTPσ directly regulates function of myelinating glia. PTPζ (PTPRZ), a member in the RPTP family, plays a negative role in oligodendrocyte differentiation during CNS development and remyelination in demyelinating CNS diseases by increasing apoptosis of mature oligodendrocytes (Harroch et al., 2002; Kuboyama et al., 2012 ).
PTPσ appears to regulate immune responses as a receptor of various immune cells by mediating constitutive signaling derived from the ECM ligands. The upstream signaling and physiological ligands that modulate PTPσ activity in immune cells or other cell types remain to be defined.
HSPGs, the known ligands of RPTPs, have been reported to inhibit IFN production by macrophages in atherosclerosis mouse model (Gordts et al., 2014) . Syndecan-1, a HSPG, could suppress various inflammatory responses and EAE development in mice and its deficiency exacerbated disease symptoms and impaired recovery in EAE mice (Zhang et al., 2013b) . In contrast, inhibition of CSPGs (also recognized ligands for RPTPs, but distinct type of proteoglycans from HSPGs) may become a therapeutic approach for autoimmune disease of MS. CSPGs are upregulated around the edge of MS lesions, whereas reduced in the center of active and chronic inactive plaques (Sobel and Ahmed, 2001) . Treatment with disaccharidic degradation product of CSPGs significantly alleviated clinical symptoms in EAE mice through reducing IFNγ and TNFα production by splenocytes (Rolls et al., 2006; Zhou et al., 2010) . Moreover, some cytokines, such as IFNγ and TGFβ1, could alter the expression level of CSPGs (Fujiyoshi et al., 2010; Smith and Strunz, 2005) .
Also as a member of type IIa RPTPs, LAR is expressed during a certain stage of thymocyte development, but not in B cells. The physiological function of LAR in immune system remains
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A C C E P T E D M A N U S C R I P T 19 controversial. One study indicates that the phosphatase activity of LAR is not required for T-cell development, repertoire selection and function (Terszowski et al., 2001) , but the other group reported that LAR deficiency affected differentiation and expansion of immature thymocytes as well as negative and positive selection (Kondo et al., 2010) . Moreover, T-cell receptor stimulation in response to calcium was significantly lower in thymocytes from LAR knockout mice, suggesting that LAR modulates T-cell receptor signaling for thymocyte differentiation.
PTPσ is a therapeutic molecular target for CNS injury and autoimmune disorders
Surmounting potent inhibition by CSPG-rich scar and its receptor-mediated downstream signaling is an important therapeutic target for achieving successful axon regeneration and functional recovery after CNS injuries. So far, the main in vivo therapeutic approach to overcome inhibition of CSPGs is enzymatic digestion with local application of ChABC. However, several disadvantages may prevent using this enzyme as a therapeutic choice for patients. ChABC cannot completely digest GAG chains from core glycoproteins and may leave undigested carbohydrate side chains on the molecules, which though less potent are still inhibitory (Lemons et al., 2003) . ChABC loses its enzymatic activity rapidly at body temperature and cannot cross the blood brain barrier. A group attempted to generate the thermostabilized ChABC (Lee et al., 2010) . A single local application could not be sufficient to overcome the inhibition due to continuous generation of CSPGs after injury. Bacterial ChABC may also induce autoimmune reactions after pulsed injections. Therefore, new strategies to overcome inhibitory effects by CSPGs are required to facilitate CNS axon regeneration and functional
recovery. An alternative approach to overcome scar-sourced inhibition is to design novel compounds that block functions of CSPGs or their receptors, including PTPσ.
In contrast to invasive approach of applying ChABC locally, systemic administration of peptides, antibodies and chemicals could block CSPG inhibition efficiently. A peptide (called intracellular PTPσ peptide, ISP) mimetic of the catalytic domain of PTPσ could overcome CSPG inhibition
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A C C E P T E D M A N U S C R I P T 20 efficiently. Systemic treatment with ISP enhanced serotonergic axon regrowth and facilitated functional recovery of locomotor and urinary systems in rat with contusive SCI (Lang et al., 2015) .
Previously, we demonstrated that peptide antagonists for LAR reduced CSPG inhibition in vitro and increased descending serotonergic axon growth and promoted sustained locomotor recovery in SCI mice after systemic administration (Fisher et al., 2011) . Consistently, silencing PTPσ with lentivirusmediated RNA interference promoted axon regeneration, synapse formation, and recovery of motor and sensory functions without affecting scar formation in rats with contusion SCI (Zhou et al., 2014) .
Because PTPσ dimerization suppresses its phosphatase activity and CSPGs activate PTPσ by preventing it from dimerizing after binding as ligands, the approach to induce and stabilize PTPσ dimerization could be effective for blocking its function. Indeed, a new PTPσ IgG monoclonal antibody could induce PTPσ dimerization and promote neurite outgrowth in SH-SY5Y cells, a neuroblastoma cell line (Wu et al., 2017 (Rolls et al., 2006; Zhou et al., 2010) . CSPG-DS treatment also markedly alleviated the clinical symptoms of EAE by reducing infiltrating T cells and activated microglia. In contrast, treatment with CS-A, a complete CS GAG chain unattached to proteoglycans, exacerbated EAE symptoms and increased infiltrated T cells in the CNS and their differentiation into pathogenic types of Th1 and Th17 (Zhou et al., 2010) . It is interesting to dissect the precise mechanisms for CSPG-DS and CS-A to regulate EAE development and whether PTPσ mediates these effects although CS-A does not bind PTPσ (Dickendesher et al., 2012) .
Prospective
PTPσ plays important physiological and pathological roles in 
